New BARDA award: AstraZeneca USA Product Name: A
Post# of 36503
![](/assets/46931549/no_avatar_available_thumb.jpg)
Product Name: AstraZeneca SARS-CoV-2 monoclonal antibody combination
View Announcement
Description:
Support development of a monoclonal antibody combination against SARS-CoV-2
Unique Impact:
A novel monoclonal antibody combination that recognizes and neutralizes SARS-CoV-2 is being developed by AstraZeneca with DARPA and BARDA as a potential preventative and post-exposure treatment to combat COVID-19.
Award Amount: $23,650,000.00
Cost Share: Yes
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)